About Jimena Vicencio

Articles by Jimena Vicencio, MD

$Ongoing Study Tests Tagraxofusp and Low-Intensity Chemotherapy for Relapsed or Refractory AML image$

Ongoing Study Tests Tagraxofusp and Low-Intensity Chemotherapy for Relapsed or Refractory AML
Aug 27, 2025
How Nutrition and Hemoglobin Levels Affect the Health of Older Adults with Myelodysplastic Syndromes
Aug 27, 2025
Early Treatment with Daratumumab After MRD Relapse May Delay Multiple Myeloma Progression
Aug 21, 2025
Could Papaya Leaf Extract Help Treat Chemotherapy-Induced Thrombocytopenia?
Aug 14, 2025
How Joining Clinical Trials Helps You and Others: Francesc Boscharell Describes His Experience in a Clinical Trial
Aug 12, 2025
Venetoclax Added to Standard Chemotherapy Shows High Response in Newly Diagnosed AML
Aug 08, 2025
What Factors Make MGUS Progress Faster?
Aug 08, 2025
How HealthTree Cure Team Volunteers Are Driving Change in Blood Cancer Care
Aug 07, 2025
Isatuximab combination (Isa-VRd) for Multiple Myeloma: Key Findings from the IMROZ Study
Aug 06, 2025
What Is Olanzapine and How Is It Used to Treat Nausea Caused by Chemotherapy
Aug 05, 2025
How Demographics and Income Affect Survival in MDS
Jul 25, 2025
$Blenrep Is Now Approved in Canada and Europe for Relapsed/Refractory Multiple Myeloma image$

Blenrep Is Now Approved in Canada and Europe for Relapsed/Refractory Multiple Myeloma
Jul 25, 2025
New Treatment Option for Pre-Fibrotic and Low-Risk Myelofibrosis
Jul 23, 2025
Real-World Outcomes of CPX-351 For High-Risk AML Patients
Jul 23, 2025
Iberdomide Combination Study Results for Transplant Ineligible Myeloma Patients
Jul 23, 2025
$Latest in Relapsed/Refractory Amyloidosis Research: Early Results of CAR-T and Bispecific Antibody Clinical Trials image$

Latest in Relapsed/Refractory Amyloidosis Research: Early Results of CAR-T and Bispecific Antibody Clinical Trials
Jul 21, 2025
Imetelstat Updates For Lower-Risk MDS
Jul 18, 2025
How Race, Income, and Access to Care impact AML Outcomes
Jul 17, 2025
$Belantamab Combination May Offer an Alternative to CAR-T for Relapsed/Refractory Myeloma image$

Belantamab Combination May Offer an Alternative to CAR-T for Relapsed/Refractory Myeloma
Jul 17, 2025
Inqovi: An All-oral Therapy Being Studied for AML Patients
Jul 09, 2025
HealthTree NYC Tour: Experts at Mount Sinai Share the Latest in Myeloma
Jul 07, 2025
Improving MPN Care Through Better Communication
Jul 07, 2025
Luspatercept Latest Research for Lower-Risk MDS
Jul 07, 2025
New Way to Engineer CAR T-Cells Could Make it More Accessible
Jul 01, 2025